BioPharma Dive March 28, 2024
The regulator gave the drug an OK after receiving more safety data from Akebia, but imposed a strict boxed warning for its use.
Dive Brief:
- The Food and Drug Administration has approved Akebia Therapeutics’ blood-boosting pill Vafseo for people with anemia from chronic kidney disease, the company said Wednesday, reversing a rejection the agency made two years ago over the drug’s safety.
- The decision came after a review of safety data from Japan, where Vafseo has been used since 2020, in addition to clinical trials Akebia completed before its initial application. Last year, the regulator approved a similarly acting pill called Jesduvroq from GSK with extensive safety restrictions and warnings.
- Vafseo can only be used in kidney disease patients...
Today's Sponsors
Today's Sponsor